
Claims:

5 1. A method for the preparation of trans- or cis- diammonium dichlorodihydroxoplatinum (IV) or derivatives thereof,

characterized in that

trans- or cis-diammoniumdichloroplatinum(II) is reacted with a solution comprising >30% peroxide at temperatures below 30%C, and the product thus obtained is dissolved in a mineral acid and subsequently precipitated with an alkaline solution.

15 2. A compound of general formula



20

wherein X_1 , X_2 = calcium, magnesium, sodium, potassium, 25 lithium ions, alkyl and/or aryl residues.

- 3. Use of the compound according to claim 2 in prophylaxis, therapy, follow-up and aftercare of diseases associated with cell growth, cell differentiation and/or cell division.
- 4. The use according to the preceding claim, characterized in that the disease is a tumor.

35

30

- 5. The use according to the preceding claim, characterized in that the compound is employed orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.
- 6. A pharmaceutical agent, comprising a compound according to claim 2, optionally together with a pharmaceutically tolerable carrier, adjuvant and/or vehicle.
- 10

5

7. The pharmaceutical agent according to the preceding claim,

characterized in that

- the carriers are selected from the group comprising fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.
- 8. The pharmaceutical agent according to any of the preceding claims, characterized in that the carriers are liposomes, siosomes and/or niosomes.
- 9. A kit, comprising the compounds according to claim 2, optionally together with information for combining the contents of the kit.
 - 10. Use of the kit according to the preceding claim in the prophylaxis or therapy of tumor diseases.